PET Tau - Neurodegenerative Disease Imaging
ConditionNeurodegenerative Disease
Trial statusRecruiting
Trial phasePhase 2, Phase 3
Trial typeInterventional
Biological sexAll
Age18-100
SponsorUniversity of Pennsylvania
About this trial
The purpose of this study is to measure the amount of a protein in the brain known as tau using an imaging procedure called Positron Emission Tomography (PET/CT). Tau has been shown to build up in the brains of patients with injury to brain cells. This study looks at neurodegenerative diseases such as frontotemporal degeneration (FTD).
Eligibility criteria
Qualifiers
Participants has been diagnosed with one of the following neurodegenerative diseases: FTD, PPA, CBD, PSP, MCI, AD, PCA, PD, PDD, DLB, MSA, ALS or FTD- ALS
Participants will be 18 years of age or older
Participants must be informed of the investigational nature of this study and provide written informed consent in accordance with institutional and federal guidelines prior to study-specific procedures. If the subject is unable to provide informed consent, the subject's legal representative may consent on behalf of the patient, but the patient will be asked to confirm assent.
Participants must be willing and able to comply with scheduled visits and imaging procedures.
Disqualifiers
Females who are pregnant or breast feeding at the time of the baseline PET/CT scan will not be eligible for this study. A urine pregnancy test will be performed in women of child-bearing potential at screening and within 24 hours of any scheduled PET/CT.
Inability to tolerate or contraindication to imaging procedures in the opinion of an investigator or treating physician
Any medical or psychological condition that, in the opinion of the investigator, would compromise the subject's safety or successful participation in the study
The investigators may choose to exclude participants with clinically significant cardiovascular disease and/or documented abnormalities on ECG out of an abundance of caution.
Trial design
Treatments tested in this trial
- 18F-AV-1451
Treatment groups
300 Participants
are divided into 1 treatment groupSponsors and collaborators
University of Pennsylvania
Lead sponsor
Avid Radiopharmaceuticals
Collaborator
Source ClinicalTrials.gov